InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 5,132 Shares

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 5,132 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $2.46, for a total value of $12,624.72. Following the sale, the insider directly owned 1,104,601 shares of the company’s stock, valued at $2,717,318.46. This trade represents a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Price Performance

NSPR opened at $1.03 on Friday. The company has a market capitalization of $48.24 million, a PE ratio of -1.37 and a beta of 0.82. The business has a 50-day moving average of $1.39 and a 200-day moving average of $1.67. InspireMD, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $2.93.

Institutional Trading of InspireMD

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ghisallo Capital Management LLC acquired a new stake in InspireMD in the 3rd quarter valued at approximately $2,221,000. Aberdeen Group plc acquired a new stake in InspireMD in the 3rd quarter valued at approximately $5,979,000. Rosalind Advisors Inc. grew its holdings in shares of InspireMD by 70.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares in the last quarter. Creative Planning acquired a new stake in shares of InspireMD during the 2nd quarter worth approximately $44,000. Finally, Virtu Financial LLC acquired a new stake in shares of InspireMD during the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on NSPR shares. Piper Sandler reissued an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Lake Street Capital set a $4.00 price objective on InspireMD in a report on Monday, May 4th. Loop Capital set a $5.00 price objective on InspireMD in a report on Tuesday, February 24th. Finally, Maxim Group started coverage on InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $4.50.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: There were no clearly positive company-specific announcements in the latest items, so investor attention is centered on the stock’s low valuation and recent trading near its 1-year low. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The most recent insider sale was small and attributed to tax withholding obligations tied to equity award vesting, which often makes the transactions less concerning than open-market selling. Multiple similar sales were also reported earlier this year. SEC filing
• Negative Sentiment: Repeated insider sales can still weigh on sentiment, as investors may view them as a sign of limited near-term upside or a lack of conviction from management, especially for a small-cap stock already trading below its recent moving averages. SEC filing

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.